TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05274724

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No teleconsultation during the ambulance journey
Description: Standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Teleconsultation during the ambulance journey
Description: teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team.
Study: NCT05791877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneuRIP
Description: Respiratory sensor to measure pulmonary function
Study: NCT05168865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
Study: NCT05348824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaf
Description: Leaf extract preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: 2.5% sodium hypochlorite (household bleaching agent)
Study: NCT05714670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Oral Capsule
Description: Curcumin 1000 mg Oral Capsule beside the standard of care
Study: NCT06611722

Intervention type: OTHER
Intervention: Psychological and Functional Assessment
Description: Assessment of Pain Sources: Patients are grouped based on intra-articular, extra-articular, or combined intra- and extra-articular hip pain.Psychological Assessment: Depression and anxiety are assessed using standardized questionnaires (e.g., BDI for depression, SAS for anxiety).Functional Assessment: Joint function and pain are evaluated using clinical and patient-reported outcome measures.

Intervention type: OTHER
Intervention: Psychological and Functional Assessment
Description: Assessment of Pain Sources: Patients are grouped based on intra-articular, extra-articular, or combined intra- and extra-articular hip pain.Psychological Assessment: Depression and anxiety are assessed using standardized questionnaires (e.g., BDI for depression, SAS for anxiety).Functional Assessment: Joint function and pain are evaluated using clinical and patient-reported outcome measures.

Intervention type: OTHER
Intervention: Psychological and Functional Assessment
Description: Assessment of Pain Sources: Patients are grouped based on intra-articular, extra-articular, or combined intra- and extra-articular hip pain.Psychological Assessment: Depression and anxiety are assessed using standardized questionnaires (e.g., BDI for depression, SAS for anxiety).Functional Assessment: Joint function and pain are evaluated using clinical and patient-reported outcome measures.
Study: NCT06615544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of indirect dental restoration
Description: The newly developed dual-cure adhesive will be used for the placement of indirect restorations.
Study: NCT06614387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Patients meeting the inclusion criteria and not having any of the exclusion criteria will be randomized 1:1 to one of two study arms - intravenous administration of blinded active drug, infliximab or vedolizumab at weeks 0, 2, 6 and 14. Infliximab will be administered at a dose 5mg/kg body weight, and vedolizumab at a dose of 300 mg (body mass \> 40 kg) and 10 mg/kg (body mass \< 40kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Patients meeting the inclusion criteria and not having any of the exclusion criteria will be randomized 1:1 to one of two study arms - intravenous administration of blinded active drug, infliximab or vedolizumab at weeks 0, 2, 6 and 14. Infliximab will be administered at a dose 5mg/kg body weight, and vedolizumab at a dose of 300 mg (body mass \> 40 kg) and 10 mg/kg (body mass \< 40kg).
Study: NCT06303778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stand Down mobile app
Description: The Stand Down mobile app is a smartphone-based stand-alone intervention designed to help persons manage drinking and alcohol-related problems on their own. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants assigned to the standard care condition will receive standard MAUD care delivered by their CPSs and will not receive access to SD-App. Three medications, naltrexone, disulfiram, and acamprosate, have been approved by the Federal Drug Administration and topiramate has been recommended by the VA/DoD clinical practice guidelines for SUD. MAUD includes these four medications. All medication decisions will be between the CPS and the Veteran and not influenced by study participation.
Study: NCT06614647

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Recurrence monitoring with circulating tumor DNA (ctDNA) as a high risk biomarker
Description: IG patients will receive the following intervention at 3, 12, 24, and 36 months post-surgery:~1) Recurrence risk stratification by ctDNA analysis of blood samples:~a) Only if ctDNA becomes positive, will imaging be performed. b) If ctDNA is positive, but recurrent disease is not detected by imaging or clinical and endoscopic evaluation, the patient will be referred back to intensified ctDNA measurements repeated every 4 months until either ctDNA becomes negative or recurrence is confirmed by subsequent imaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring for late adverse effects with electronic patient reported outcome measures (ePROMs)
Description: 2) Collection and analyses of ePROMs to identify whether patients suffer from organ-specific late effects or biopsychosocial late effects and monitor of health related quality of life and the impact of late adverse effects hereon.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic treatment of organ-specific late effects and/or biopsychosocial late effects
Description: 3) When needed, standardized treatment for organ-specific late effects according to newly published national guidelines at specialized centers. Further, online cognitive behavioral therapy is offered to patients suffering from severe biopsychosocial late effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital care-guide for long-term follow-up after cancer treatment
Description: Use of a digital care-guide from study inclusion to guide the patient trough the follow-up program, in the form of a personalized smart phone app.
Study: NCT05314010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIL62
Description: Phase 1b:participants will receive IV MIL62 500 mg or 1000 mg on Day 1 and Day 15.~Phase 3:Participants will receive IV MIL62 on Day 1, Day 15 and Day 183 of the RCP at the dose confirmed in the phase Ib. The participants who enter the OLP will receive IV MIL62 on Day 1 and matching placebo on Day 15, followed by a single IV dose of MIL62 every 6 months until maximum of 6 months after the last participant enters the OLP.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase 3:Participants will receive IV placebo matched to MIL62 on Day 1, Day 15 and Day 183 of the RCP. The participants who enter the OLP will receive IV MIL62 on both Day 1 and Day 15, followed by a single IV dose of MIL62 every 6 months until maximum of 6 months after the last participant enters the OLP.
Study: NCT06685185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0363-1063
Description: NNC0363-1063 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0363-1063
Description: NNC0363-1063 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0363-1063
Description: NNC0363-1063 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0363-1063
Description: NNC0363-1063 will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Insulin degludec will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Insulin degludec will be administered subcutaneously.
Study: NCT05436054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picoprep
Description: 200 patients will be randomised to this arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plenvu
Description: 200 patients will be randomised to this arm
Study: NCT05700721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given by IV (vein)
Study: NCT04174560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.4 Challenge Pool
Description: Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.4 Challenge Pool
Description: Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.4 Challenge Pool
Description: Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.
Study: NCT06697535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0061
Description: Administered orally with a dose reduction over time as specified in Arm descriptions. Tablets are taken within a specific time frame after meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0061
Description: Administered orally with a dose reduction over time as specified in Arm descriptions. Tablets are taken within a specific time frame after meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Glucocorticoids
Description: Administered intravenously with a gradually decreasing dose over time, as specified in the Standard Dose Glucocorticoids arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Glucocorticoids
Description: Administered intravenously with a gradually decreasing dose over time, as specified in the Standard Dose Glucocorticoids arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Glucocorticoids
Description: Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucocorticoids
Description: Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.
Study: NCT06698211

Intervention type: DRUG
Intervention: Posaconazole tablet
Description: Posaconazole tablet will be given at a dose of 300mg q12h on day 1 and 300mg qd from day 2 for patients who receive HSCT as the primary prophylaxis of IFD, after which the Posaconazole plasma concentration on day 5 will be examined. Once patients developed GI GVHD, first line therapy and second line treatment will be reviewed according to the condition, besides which the Posaconazole plasma concentration would be detected again on the first, third and fifth day after onset of GI GVHD symptoms to monitor the impact of GI GVHD on the Posaconazole plasma concentration.
Study: NCT06697054

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy with either ICG or carbon dye injection to cervix
Description: Either laparatomy or laparoscopy wil be performed to detect sentinel node stained with either ICG or carbon dye injected to cervix. A hemipelvis in which a sentinel is not found will be subjected to full lymphadenectomy.
Study: NCT06697938

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative SBRT for the Primary Lesion of Breast Cancer
Description: SBRT for Primary Lesion of Breast Cancer, Radiation Dose: Primary Lesion ≤3 cm, GTV 24Gy/3F; Primary Lesion \>3 cm, GTV 30Gy/5F.
Study: NCT06696664

Intervention type: DRUG
Intervention: PEG-IFN-α
Description: chronic hepatitis B (CHB) who were continuously treated with pegylated interferon (PEG-IFN - α) for more than 24 weeks

Intervention type: DRUG
Intervention: PEG-IFN-α
Description: chronic hepatitis B (CHB) who were continuously treated with pegylated interferon (PEG-IFN - α) for more than 24 weeks
Study: NCT06696365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: The intermittent theta burst (iTBS) will be delivered using the MagVenture MagPro X100 stimulator equipped with a Cool B-70 A/P (combined active \& sham) figure of eight coil. MagVenture MagPro X100 is available commercially and has been FDA approved to treat major depressive disorder and obsessive-compulsive disorder.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: The intermittent theta burst (iTBS) will be delivered using the MagVenture MagPro X100 stimulator equipped with a Cool B-70 A/P (combined active \& sham) figure of eight coil. MagVenture MagPro X100 is available commercially and has been FDA approved to treat major depressive disorder and obsessive-compulsive disorder.
Study: NCT06697249

Intervention type: OTHER
Intervention: Analysis of postoperative CT scans checking for the feasibility of transcatheter valve-in-root implantation
Description: CT scans of patients after biological root replacement and root repair were assessed with the 3mensio Software (Aortic valve package, 3mensio 10.1, Pie Medical Imaging. Before carrying out the measurements, markers for alignment of the aortic root and ascending aorta were placed manually. The annular area was measured for both groups. In patients after biological root replacement the area of the annulus was defined as the ring of the initial aortic valve prosthesis. Coronary buttons were measured at their lowest and highest point to define partial or full position below the valve level and the general button size. For assessment of the annular-to-coronary distance, the lower edge of the coronary button was chosen. VTC was assessed after root replacement in patients who had at least one coronary partially under the level of the valve. For this measurement a virtually inserted valve was placed in the bioprosthetic frame.

Intervention type: OTHER
Intervention: Analysis of postoperative CT scans checking for the feasibility of transcatheter valve-in-root implantation
Description: CT scans of patients after biological root replacement and root repair were assessed with the 3mensio Software (Aortic valve package, 3mensio 10.1, Pie Medical Imaging. Before carrying out the measurements, markers for alignment of the aortic root and ascending aorta were placed manually. The annular area was measured for both groups. In patients after biological root replacement the area of the annulus was defined as the ring of the initial aortic valve prosthesis. Coronary buttons were measured at their lowest and highest point to define partial or full position below the valve level and the general button size. For assessment of the annular-to-coronary distance, the lower edge of the coronary button was chosen. VTC was assessed after root replacement in patients who had at least one coronary partially under the level of the valve. For this measurement a virtually inserted valve was placed in the bioprosthetic frame.
Study: NCT06697626

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin, B-vitamins and vitamin D
Description: Intervention twice daily with:~10g chicory inulin 100µg folic acid 5µg vitamin B12 5mg vitamin B6 2.5mg riboflavin 5µg vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: A twice daily placebo drink with similar energy content but without the additional nutrient provision
Study: NCT06696885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile based video games and task based training
Description: The experimental group received a mobile-based applications for 20 minutes and tasks-based training for 20 minutes per day (a total of 40 minutes), 6 days a week for 17 weeks. The time between each game was divided accordingly to work on improving hand function. The games and tasks were divided into three broad categories, Easy, Moderate, Difficult. Each category is applied for 6 weeks
Study: NCT06697795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Assisted Hypnotherapy
Description: Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic neck pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
Study: NCT06697236

Intervention type: OTHER
Intervention: EPICES score
Description: EPICES score used to group participants as precarious and non precarious.

Intervention type: OTHER
Intervention: EPICES score
Description: EPICES score used to group participants as precarious and non precarious.

Intervention type: OTHER
Intervention: PICS evaluation
Description: * Assessment of physical symptoms using the Timed up and go test (TUG)~* Assessment of depressive symptoms using the PHQ-8 and anxiety symptoms using the GAD-7 and screening for post-traumatic stress disorder using the IES-R~* Assessment of cognitive disorders using the MoCA

Intervention type: OTHER
Intervention: PICS-F evaluation
Description: * Assessment of depressive symptoms using the PHQ-8 and anxiety symptoms using the GAD-7~* Screening for post-traumatic stress disorder using the IES-R
Study: NCT06697080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cells
Study: NCT05859997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRL-301
Description: Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
Study: NCT06221046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream D
Description: Prevention~1. Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~2. Avoid rubbing/scrubbing~3. Reduce exposure to moisture as much as possible~4. Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~1. Continue with prevention methods, apply CREAM ARM 2 as a barrier product after every fecal incontinence event~2. Discontinue CREAM ARM 2 use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~1. Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~2. Discontinue use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Prevention~1. Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~2. Avoid rubbing/scrubbing~3. Reduce exposure to moisture as much as possible~4. Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~1. Continue with prevention methods, apply CREAM ARM 1 as a barrier product after every fecal incontinence event~2. Discontinue CREAM ARM 1 use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~1. Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~2. Discontinue use after the skin has healed~3. If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment